In July last year, SR One and Lilly Ventures, the corporate venturing divisions of multinational pharmaceutical conglomerates GlaxoSmithKline and Eli Lilly respectively, co-led a $24m series A round for Nimbus Discovery.
Nimbus Discovery, a corporate venturing-backed US-based biopharmaceutical company, has hired as its executive chairman Daniel Lynch (pictured), former chief executive at peer ImClone Systems.
He’s taking over the role from Bruce Booth, a Nimbus co-founder and partner at venture capital firm Atlas Venture, who is remaining on the company’s board.
Booth said: “One of Dan’s many strengths is his ability to drive young companies to achieve their goals. In particular, his proven track record in creating value through partnerships will…
